Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210609 | 0.75 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL21078140 | 0.73 | GRM5 (0.43) | GPR183GRM5PIK3CDPIK3R1NPC1 | |
| SCHEMBL15227669 | 0.72 | — | — | |
| SCHEMBL20004193 | 0.72 | GRM5 (0.43) | GPR183GRM5PIK3CDPIK3R1NPC1 | |
| SCHEMBL1463447 | 0.72 | CHRNA4 (0.61) | CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL23777005 | 0.70 | SMN1; SMN2 (0.41) | GPR183GRM5PIK3CDPIK3R1NPC1 | |
| SCHEMBL1463557 | 0.70 | CHRNB2 (0.65) | CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL26286133 | 0.68 | PIK3CD (0.39) | GPR183GRM5PIK3CDPIK3R1NPC1 | |
| SCHEMBL301155 | 0.68 | — | — | |
| SCHEMBL12582055 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | claimed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | claimed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | claimed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | claimed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GPR183 634/4885GRM5 1935/4885PIK3CD 554/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GPR183 634/4885GRM5 1935/4885PIK3CD 554/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GPR183 634/4885GRM5 1935/4885PIK3CD 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.